Show simple item record

dc.contributor.authorTurco, F
dc.contributor.authorArmstrong, A
dc.contributor.authorAttard, G
dc.contributor.authorBeer, TM
dc.contributor.authorBeltran, H
dc.contributor.authorBjartell, A
dc.contributor.authorBossi, A
dc.contributor.authorBriganti, A
dc.contributor.authorBristow, RG
dc.contributor.authorBulbul, M
dc.contributor.authorCaffo, O
dc.contributor.authorChi, KN
dc.contributor.authorClarke, CS
dc.contributor.authorClarke, N
dc.contributor.authorDavis, ID
dc.contributor.authorde Bono, J
dc.contributor.authorDuran, I
dc.contributor.authorEeles, R
dc.contributor.authorEfstathiou, E
dc.contributor.authorEfstathiou, J
dc.contributor.authorEvans, CP
dc.contributor.authorFanti, S
dc.contributor.authorFeng, FY
dc.contributor.authorFizazi, K
dc.contributor.authorFrydenberg, M
dc.contributor.authorGeorge, D
dc.contributor.authorGleave, M
dc.contributor.authorHalabi, S
dc.contributor.authorHeinrich, D
dc.contributor.authorHigano, C
dc.contributor.authorHofman, MS
dc.contributor.authorHussain, M
dc.contributor.authorJames, N
dc.contributor.authorJones, R
dc.contributor.authorKanesvaran, R
dc.contributor.authorKhauli, RB
dc.contributor.authorKlotz, L
dc.contributor.authorLeibowitz, R
dc.contributor.authorLogothetis, C
dc.contributor.authorMaluf, F
dc.contributor.authorMillman, R
dc.contributor.authorMorgans, AK
dc.contributor.authorMorris, MJ
dc.contributor.authorMottet, N
dc.contributor.authorMrabti, H
dc.contributor.authorMurphy, DG
dc.contributor.authorMurthy, V
dc.contributor.authorOh, WK
dc.contributor.authorEkeke, ON
dc.contributor.authorOst, P
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorPadhani, AR
dc.contributor.authorParker, C
dc.contributor.authorPoon, DMC
dc.contributor.authorPritchard, CC
dc.contributor.authorRabah, DM
dc.contributor.authorRathkopf, D
dc.contributor.authorReiter, RE
dc.contributor.authorRubin, M
dc.contributor.authorRyan, CJ
dc.contributor.authorSaad, F
dc.contributor.authorSade, JP
dc.contributor.authorSartor, O
dc.contributor.authorScher, HI
dc.contributor.authorShore, N
dc.contributor.authorSkoneczna, I
dc.contributor.authorSmall, E
dc.contributor.authorSmith, M
dc.contributor.authorSoule, H
dc.contributor.authorSpratt, DE
dc.contributor.authorSternberg, CN
dc.contributor.authorSuzuki, H
dc.contributor.authorSweeney, C
dc.contributor.authorSydes, MR
dc.contributor.authorTaplin, M-E
dc.contributor.authorTilki, D
dc.contributor.authorTombal, B
dc.contributor.authorTürkeri, L
dc.contributor.authorUemura, H
dc.contributor.authorUemura, H
dc.contributor.authorvan Oort, I
dc.contributor.authorYamoah, K
dc.contributor.authorYe, D
dc.contributor.authorZapatero, A
dc.contributor.authorGillessen, S
dc.contributor.authorOmlin, A
dc.date.accessioned2022-04-26T11:00:47Z
dc.date.available2022-04-26T11:00:47Z
dc.date.issued2022-02-17
dc.identifier.citationEuropean urology, 2022en
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5094
dc.identifier.eissn1873-7560en_US
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2022.02.010en_US
dc.identifier.doi10.1016/j.eururo.2022.02.010
dc.description.abstractPatients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleWhat Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.en
dc.typeJournal Article
dcterms.dateAccepted2022-02-04
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1016/j.eururo.2022.02.010en
rioxxterms.licenseref.startdate2022-02-17
dc.relation.isPartOfEuropean urologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.embargo.termsNot knownen_US
icr.researchteamProstate Cancer Targeted Therapy Group
icr.researchteamOncogenetics
dc.contributor.icrauthorParker, Chrisen_US
dc.contributor.icrauthorEeles, Rosalinden_US
dc.contributor.icrauthorDe Bono, Johannen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/